LDL-C, ApoB and Lp(a): what does each test actually show?
Three related measurements. Three different clinical questions. None should be interpreted in isolation.
The quick answer
Cholesterol cargo, particle number, and inherited risk are not the same thing.
LDL-C estimates how much cholesterol is carried within the LDL fraction. ApoB estimates how many atherogenic particles are circulating. Lp(a) measures a specific, largely inherited LDL-like particle that adds risk beyond the standard lipid panel. Most people begin with a standard lipid profile; ApoB becomes especially informative when particle number may be underestimated by LDL-C, while Lp(a) is generally a once-in-adulthood risk test.
Interpretive mapFrom isolated data to a responsible decision
01LDL-C — the cargo
02ApoB — the particle count
03Lp(a) — the inherited signal
LDL-C — the cargo
Reports the concentration of cholesterol carried in LDL-related particles. It remains the principal screening and treatment target in current Brazilian and U.S. guidelines.
ApoB — the particle count
Each LDL, IDL, VLDL-remnant and Lp(a) particle carries one ApoB molecule. ApoB therefore estimates the total number of circulating atherogenic particles.
Lp(a) — the inherited signal
Measures one specific ApoB-containing particle linked to apolipoprotein(a). Its concentration is more than 90% genetically determined and usually changes little with lifestyle.
The core distinctionLDL-C asks how much cholesterol is being carried. ApoB asks how many atherogenic particles are carrying it. Lp(a) asks how much inherited particle-related risk is present.
September 2026 evidence update
Lp(a)HORIZON did not meet its primary cardiovascular endpoint in the overall study population.10,11
Headline results reported; full analysis pending.
On September 4, 2026, the sponsor reported that Lp(a)HORIZON did not reduce its primary composite cardiovascular endpoint with pelacarsen versus placebo in the overall study population, although lower Lp(a) levels were achieved. The trial enrolled 8,323 people with elevated Lp(a) and established cardiovascular disease. Complete results were not included in the announcement and are expected at a future medical congress.
Side by side
One blood draw can answer three different questions.
Marker
What it measures
Best-established role
Common limitation
LDL-C
Cholesterol concentration inside the LDL fraction
Standard risk assessment, treatment goals, and response monitoring
May not reflect particle number when cholesterol per particle varies; calculation becomes less reliable with high triglycerides
ApoB
Total concentration of atherogenic ApoB-containing particles
Refining residual risk and detecting LDL-C/ApoB discordance
Often adds little when it agrees with LDL-C/non-HDL-C; access and targets vary
Lp(a)
Concentration of a specific inherited LDL-like particle
Identifying a lifelong risk enhancer and informing family screening
Assay and unit differences complicate interpretation; current treatment acts mainly through broader risk reduction
MERHI ONE Evidence Map
What the evidence supports—and what it does not.
Each rating applies to the exact statement shown. A strong biological association is not automatically proof that every test should be ordered for everyone or that every way of changing the number improves outcomes.
01Strong
ApoB-containing lipoproteins, including LDL, play a causal role in atherosclerotic cardiovascular disease.2,4,5
Converging genetic, epidemiologic, mechanistic, and randomized-treatment evidence supports causality. The clinical effect of therapy still depends on the intervention, the amount and duration of reduction, and baseline absolute risk.
02Strong
Lowering LDL-C with proven therapies reduces major vascular events.2,4
In the Cholesterol Treatment Trialists’ meta-analysis, each 1 mmol/L (about 38.7 mg/dL) reduction in LDL-C was associated with a roughly one-fifth proportional reduction in major vascular events. Absolute benefit is larger when baseline cardiovascular risk is higher.
03Strong biological basis
ApoB estimates atherogenic particle number more directly than LDL-C.1,8
There is one ApoB molecule on each major atherogenic particle. LDL-C measures cholesterol mass, which can vary from particle to particle; the two markers therefore sometimes disagree.
04Moderate / guideline-supported
ApoB is especially useful with high triglycerides, diabetes, obesity, metabolic or cardiovascular-kidney-metabolic disease, or known ASCVD.1,2,3
The 2025 Brazilian guideline gives a strong recommendation with moderate certainty for ApoB to assist risk assessment and therapy when triglycerides exceed 150 mg/dL. The 2026 U.S. guideline supports selective use to assess residual risk, including after LDL-C and non-HDL-C goals are reached.
05Brazil: strong recommendation / moderate certainty
Measure Lp(a) at least once in adulthood when available.1,2,3,6,7
Brazilian 2025 and U.S. 2026 guidelines recommend at least one adult measurement. NLA and EAS guidance also support once-in-adulthood testing because the concentration is largely inherited and relatively stable. The strength-and-certainty label shown here is the Brazilian guideline's classification for the general population, not a universal grade shared by every organization.
06Strong
Elevated Lp(a) is a causal risk factor for ASCVD and calcific aortic valve stenosis.6,7,9
Genetic and observational evidence supports a continuous association across ancestries. Elevated Lp(a) can matter even when LDL-C is otherwise well controlled.
07Strong laboratory guidance
Do not convert Lp(a) between mg/dL and nmol/L with one fixed factor.1,6,8,9
Apolipoprotein(a) varies in molecular size between people, so mass and particle concentration are not linked by a universal conversion. Brazilian and European guidance prefer an isoform-insensitive assay reported in nmol/L when available.
08Limited direct effect on Lp(a)
Healthy habits support cardiovascular prevention even when Lp(a) changes little.2,6,7,9
Healthy eating, physical activity, weight management, and control of other risk factors remain important. Their value does not depend on substantially lowering genetically determined Lp(a) itself.
09Headline outcome / full report pending
Lowering Lp(a) alone does not establish cardiovascular benefit.10,11
According to the September 4 sponsor announcement, Lp(a)HORIZON did not meet its primary cardiovascular endpoint in the overall study population despite lowering Lp(a) with pelacarsen. Complete results are still pending, so no event rates, subgroup findings, or safety conclusions can yet be independently assessed from the announcement.
10Guideline-supported selective use
ApoB complements assessment; it does not replace LDL-C in every situation.1,2,3
Current Brazilian and U.S. guidance retains LDL-C and non-HDL-C as primary targets while expanding selective ApoB use. For most people, the markers are highly correlated and provide similar information.
United States — 2026 ACC/AHA
- Lp(a): measure at least once in adulthood; ≥125 nmol/L or ≥50 mg/dL is a risk-enhancing level.
- ApoB: selective use for residual risk in CKM syndrome, type 2 diabetes, high triglycerides, known ASCVD, or discordant results.
- LDL-C goals: <100 mg/dL for borderline/intermediate primary-prevention risk; <70 mg/dL for high risk; <55 mg/dL for very-high-risk ASCVD.
- PREVENT-ASCVD is the current guideline framework for eligible adults ages 30–79 without known ASCVD or subclinical disease and LDL-C 70–189 mg/dL.
Europe — 2025 ESC/EAS
- Lp(a): consider at least one measurement in adulthood.
- Levels >50 mg/dL, with reference to >105 nmol/L, are used as a risk modifier.
- A second measurement can be reasonable after menopause, particularly when the earlier premenopausal result was borderline.
- Interpretation and treatment decisions still depend on absolute cardiovascular risk and local guidance.
Brazil — 2025 SBC
- Lp(a): measure once in the general adult population when available; ≥125 nmol/L or ≥50 mg/dL is relevant to risk assessment. The recommendation is strong, with moderate certainty.
- Prefer an isoform-independent assay reported in nmol/L; do not use a fixed conversion from mg/dL.
- ApoB: may assist risk assessment when triglycerides are >150 mg/dL; non-HDL-C remains a practical, no-extra-cost alternative.
- LDL-C goals by risk: <115 low, <100 intermediate, <70 high, <50 very high, and <40 mg/dL extreme risk.
Reading combinations
When the numbers disagree, the pattern matters.
LDL-C high + ApoB high
Cholesterol burden and atherogenic particle number point in the same direction. The next step is to determine overall risk, secondary causes, family history, and the appropriate target.
LDL-C apparently acceptable + ApoB high
There may be more cholesterol-depleted atherogenic particles than LDL-C suggests. This pattern is more common with high triglycerides, diabetes, obesity, insulin resistance, and metabolic syndrome.
LDL-C high + ApoB not elevated
Particles may be relatively cholesterol-rich. This does not automatically make elevated LDL-C harmless; guideline targets and the total risk assessment still apply.
Lp(a) high at any LDL-C or ApoB
Lp(a) adds inherited risk that can persist despite otherwise favorable numbers. Intensify control of modifiable risk factors and consider testing first-degree relatives.
All three favorable
This is reassuring for lipoprotein-related risk but does not exclude hypertension, diabetes, smoking risk, inflammation, kidney disease, or existing atherosclerosis.
Common interpretation errors
A sophisticated test can still be used badly.
The principal danger is turning a useful marker into a diagnosis, a guarantee, or a treatment plan by itself.
‘My LDL-C is normal, so my risk is zero’
LDL-C is one part of risk. ApoB discordance, elevated Lp(a), blood pressure, diabetes, kidney disease, smoking, family history, and established plaque can change the picture.
‘ApoB and Lp(a) are the same test’
Lp(a) is one specific ApoB-containing particle. ApoB counts the broader population of atherogenic particles; it does not reveal how much of that count is Lp(a).
‘High HDL-C cancels high LDL-C or ApoB’
HDL-C is a risk marker but has not been shown to neutralize exposure to atherogenic ApoB-containing particles.
‘A supplement can normalize inherited Lp(a)’
No supplement has proven that lowering Lp(a) through supplementation prevents cardiovascular events. Niacin can lower the number but is not recommended for this purpose because outcome benefit was not demonstrated.
‘I can convert any Lp(a) result online’
A fixed conversion between mg/dL and nmol/L is analytically unreliable because apo(a) particle size varies.
‘One result tells me which medication and dose to take’
Treatment requires absolute risk, prior disease, comorbidities, baseline values, response, adverse effects, preferences, and country-specific guidance.
What a wrong interpretation can cause
- False reassurance from one favorable marker
- Anxiety from inherited risk without context
- Unnecessary repeat Lp(a) testing
- Inappropriate supplements or self-medication
- Stopping effective therapy because Lp(a) did not fall
- Ignoring family screening when Lp(a) is high
A practical next step
Turn three numbers into one cardiovascular-risk conversation.
- 01
Start with a standard lipid profile and confirm the clinical context, fasting status if relevant, prior results, medications, and metabolic stability.
- 02
Estimate absolute cardiovascular risk and identify established ASCVD, diabetes, kidney disease, smoking, blood pressure, family history, and possible familial hypercholesterolemia.
- 03
Consider ApoB when triglycerides are elevated, LDL-C and non-HDL-C appear discordant, cardiometabolic risk is present, or residual risk could change management.
- 04
Measure Lp(a) at least once in adulthood; repeat only when a defined clinical or analytical reason exists.
- 05
If Lp(a) is high, intensify modifiable-risk management and discuss first-degree-relative testing rather than promising that lifestyle will normalize the marker.
- 06
Set the LDL-C/non-HDL-C—and, when appropriate, ApoB—goal according to the guideline and the individual’s risk, then monitor response at a clinically appropriate interval.
Frequently asked
Direct answers to the questions patients actually ask.
Which is better: LDL-C or ApoB?+
For routine care, LDL-C remains the main validated target. ApoB can be more informative when cholesterol content and particle number are discordant, especially with high triglycerides or cardiometabolic disease.
Is Lp(a) included in ApoB?+
An Lp(a) particle carries one ApoB molecule, so it contributes to total ApoB. However, an ApoB result cannot tell how much Lp(a) is present; Lp(a) requires its own assay.
Does Lp(a) require fasting?+
Usually no. Lp(a) is relatively stable and not meaningfully changed by an ordinary meal, although measurement should ideally occur in a stable clinical state and follow laboratory instructions.
Does once-in-adulthood testing mean it should never be repeated?+
Routine repetition is usually unnecessary. The 2025 ESC/EAS update says a second measurement can be reasonable after menopause, particularly when an earlier premenopausal result was borderline. Other defined clinical or analytical reasons may also justify repeat testing; this is not a recommendation for annual testing in everyone.
Can statins raise Lp(a)? Should they be stopped?+
Statins may leave Lp(a) unchanged or increase it slightly, but their proven cardiovascular benefit through LDL-C lowering generally outweighs that change. Do not stop prescribed therapy without medical review.
If my Lp(a) is high, should my family be tested?+
Current Brazilian, U.S., NLA, and EAS guidance supports cascade testing of first-degree relatives in families with elevated Lp(a), premature ASCVD, or related high-risk features.
Can I calculate my own target from this article?+
No. Targets differ by country and risk category. A personal decision requires clinical history, prior disease, comorbidities, medications, preferences, and confirmation of the laboratory context.
Continue reading
What does coronary calcium add to lipid results?
Read the guide to CAC, a zero score, and its limitations →Claim-level foundation
References
Priority was given to current national guidelines, professional-society statements, laboratory guidance, and high-level evidence. The September 2026 trial update is identified as a sponsor announcement, not a complete peer-reviewed results paper.
- 01Open source ↗
Sociedade Brasileira de Cardiologia · 2025
Brazilian Guideline on Dyslipidemias and Prevention of Atherosclerosis
- 02Open source ↗
ACC / AHA / Multisociety · 2026
Guideline on the Management of Dyslipidemia
- 03Open source ↗
American College of Cardiology · 2026
How the 2026 Dyslipidemia Guideline Changes Practice
- 04Open source ↗
Cholesterol Treatment Trialists’ Collaboration · 2010
More intensive lowering of LDL cholesterol: meta-analysis of 170,000 participants
- 05Open source ↗
European Atherosclerosis Society · 2017
Low-density lipoproteins cause atherosclerotic cardiovascular disease
- 06Open source ↗
European Atherosclerosis Society · 2022
Lipoprotein(a) in ASCVD and aortic stenosis: consensus statement
- 07Open source ↗
National Lipid Association · 2024
Focused update on use of lipoprotein(a) in clinical practice
- 08Open source ↗
Association for Diagnostics & Laboratory Medicine · 2024; correction 2025
Guidance on measurement and reporting of lipids and lipoproteins
- 09Open source ↗
American College of Cardiology · 2023; reviewed 2026
Lipoprotein(a): testing, treatment, and guideline recommendations
- 10Open source ↗
Novartis · September 4, 2026
Lp(a)HORIZON Phase III topline results for pelacarsen
- 11Open source ↗
Ionis Pharmaceuticals · September 4, 2026
Corroborating sponsor announcement on Lp(a)HORIZON
- 12Open source ↗
European Society of Cardiology / European Atherosclerosis Society · 2025
Focused Update of the Guidelines for the Management of Dyslipidaemias
Editorial record